Can Chen

Title: Can Chen - Innovator in Therapeutic Agents

Introduction

Can Chen is a prominent inventor based in Zhejiang, China. He has made significant contributions to the field of therapeutic agents, particularly in the development of innovative treatments involving nucleic acids and CAR-modified immune cells. His work is paving the way for advancements in cancer therapy.

Latest Patents

Can Chen holds a patent for "Therapeutic agents comprising nucleic acids and CAR-modified immune cells, and uses thereof." This patent describes a therapeutic agent that includes a nucleic acid with a labeling polypeptide coding sequence designed for introduction into tumor cells and/or cancer cells. The agent comprises two compositions: the first includes a nucleic acid that can modify the surface of tumor cells, while the second consists of chimeric antigen receptor modified immune cells that specifically recognize and bind to the extracellular antigen determining region. This innovative therapeutic agent aims to achieve a synergistic therapeutic effect.

Career Highlights

Can Chen is associated with Hangzhou Converd Co., Ltd., where he continues to work on groundbreaking research and development in the field of immunotherapy. His expertise and innovative approach have positioned him as a key figure in the industry.

Collaborations

Can Chen collaborates with notable colleagues, including Fang Hu and Lin Xiao, who contribute to his research endeavors and help advance the development of therapeutic agents.

Conclusion

Can Chen's work in the field of therapeutic agents represents a significant advancement in cancer treatment. His innovative approach and dedication to research are making a lasting impact on the medical community.